CA2872856A1 - Methodes permettant d'empecher la formation de biofilms - Google Patents

Methodes permettant d'empecher la formation de biofilms Download PDF

Info

Publication number
CA2872856A1
CA2872856A1 CA2872856A CA2872856A CA2872856A1 CA 2872856 A1 CA2872856 A1 CA 2872856A1 CA 2872856 A CA2872856 A CA 2872856A CA 2872856 A CA2872856 A CA 2872856A CA 2872856 A1 CA2872856 A1 CA 2872856A1
Authority
CA
Canada
Prior art keywords
antibody
pnag
seq
set forth
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2872856A
Other languages
English (en)
Inventor
Jeremy Yethon
Astrid REY
Sylvie LEFORT
Laurent Fraisse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA2872856A1 publication Critical patent/CA2872856A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
CA2872856A 2012-05-07 2013-05-06 Methodes permettant d'empecher la formation de biofilms Abandoned CA2872856A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261643650P 2012-05-07 2012-05-07
US61/643,650 2012-05-07
FRFR1352399 2013-03-18
PCT/US2013/039724 WO2013169657A1 (fr) 2012-05-07 2013-05-06 Méthodes permettant d'empêcher la formation de biofilms

Publications (1)

Publication Number Publication Date
CA2872856A1 true CA2872856A1 (fr) 2013-11-14

Family

ID=48464117

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2872856A Abandoned CA2872856A1 (fr) 2012-05-07 2013-05-06 Methodes permettant d'empecher la formation de biofilms

Country Status (8)

Country Link
EP (1) EP2847216A1 (fr)
CN (1) CN104662042A (fr)
AU (1) AU2013259786A1 (fr)
CA (1) CA2872856A1 (fr)
HK (1) HK1208475A1 (fr)
MX (1) MX2014013637A (fr)
SG (1) SG11201407209YA (fr)
WO (1) WO2013169657A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230053458A1 (en) * 2019-11-22 2023-02-23 Alopexx, Inc. Methods for providing continuous therapy against pnag comprising microbes

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
AU660297B2 (en) 1990-11-09 1995-06-22 Stephen D. Gillies Cytokine immunoconjugates
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1724282B1 (fr) 1997-05-21 2013-05-15 Merck Patent GmbH Procédé de production de protéines non-immunogènes
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2341029A1 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
EP1006183A1 (fr) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Récepteurs Fc recombinantes et solubles
EP1051432B1 (fr) 1998-12-08 2007-01-24 Biovation Limited Modification de l'immunogenicite de proteines
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2495251C (fr) 2002-08-14 2018-03-06 Macrogenics, Inc. Anticorps specifiques du recepteur fc.gamma.riib et procedes d'utilisation de ces anticorps
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1697415A1 (fr) 2003-11-12 2006-09-06 Biogen Idec MA Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
EP1697520A2 (fr) 2003-12-22 2006-09-06 Xencor, Inc. Polypeptides fc a nouveaux sites de liaison de ligands fc
US20080089892A1 (en) 2004-01-12 2008-04-17 Eli Lilly And Co. Fc Region Variants
EP1737890A2 (fr) 2004-03-24 2007-01-03 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
WO2005123780A2 (fr) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
WO2006085967A2 (fr) 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
EP2471813B1 (fr) 2004-07-15 2014-12-31 Xencor, Inc. Variantes optimisées de Fc
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee

Also Published As

Publication number Publication date
AU2013259786A1 (en) 2014-11-20
MX2014013637A (es) 2015-02-05
CN104662042A (zh) 2015-05-27
EP2847216A1 (fr) 2015-03-18
HK1208475A1 (en) 2016-03-04
SG11201407209YA (en) 2014-12-30
WO2013169657A1 (fr) 2013-11-14

Similar Documents

Publication Publication Date Title
US11136398B2 (en) PDGF receptor beta binding polypeptides
US20230399388A1 (en) Methods for treating inflammation using antibodies to kallidin and des-arg10-kallidin
EP2164869A2 (fr) PROTEINES DE LIAISON A L'ANTIGENE CIBLANT L'ORF0657n DE S. AUREUS
US11814441B2 (en) Bi-specific antigen-binding polypeptides
KR102120620B1 (ko) 면역글로불린을 이용한 점막염의 치료
US20150086601A1 (en) Methods for preventing biofilm formation
CA2872856A1 (fr) Methodes permettant d'empecher la formation de biofilms
US20150210755A1 (en) Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection
Li et al. Antibodies to kallidin and des-Arg 9-kallidin

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180510